AVTX · Avalo Therapeutics Inc
United States · RS rating 12 · As of 2026-10-14
| Price | 11.84 USD |
|---|---|
| 1-day change | -1.4% |
| RS rating (overall / 1M / 3M / 12M) | 12 / 8 / 10 / 30 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 29 / 19 / 39 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +15.3% |
| Sales growth Q/Q | -100.0% |
| Distance from 52-week high | +48.2% |
| Market cap (USD) | $336.1M |